Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06108232 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
A Phase 2 study of Follicular Lymphoma and Tumor, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06108232: Recruiting Phase 2 study of Follicular Lymphoma and Tumor, sponsored by M.D. Anderson Cancer Center.
NCT06108232 is a Phase 2 study of Follicular Lymphoma and Tumor that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06108232, a Phase 2 study of Follicular Lymphoma and Tumor, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG CC-99282
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT06108232 shows while recruiting
NCT06108232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Obinutuzumab is the first listed.
NCT06108232 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06108232 about?
NCT06108232 is a clinical study titled "Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma". To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL
What is the current status of trial NCT06108232?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2024-03-15. Estimated completion is 2027-12-31.
What conditions does trial NCT06108232 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Tumor.
What interventions are being tested in trial NCT06108232?
The interventions under investigation include: Obinutuzumab (DRUG), CC-99282 (DRUG).
Who is sponsoring clinical trial NCT06108232?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06108232 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06108232's enrollment target sits among peer trials
36 61st of 89 higher than 27 of 89 other Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI